Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:AVDL NASDAQ:SDGR NASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.36-0.3%$4.90$3.21▼$7.18$1.53B0.734.46 million shs2.37 million shsAVDLAvadel Pharmaceuticals$14.76+1.0%$11.54$6.38▼$16.66$1.43B1.571.37 million shs1.65 million shsSDGRSchrodinger$19.51-1.3%$20.52$16.60▼$28.47$1.44B1.791.39 million shs703,990 shsYMABY-mAbs Therapeutics$8.55+0.1%$6.12$3.55▼$16.11$388.50M0.532.18 million shs398,287 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx0.00%+4.09%+46.88%+65.19%+2.91%AVDLAvadel Pharmaceuticals0.00%-3.15%+33.21%+55.53%-2.70%SDGRSchrodinger0.00%-3.99%-0.10%-10.05%-7.23%YMABY-mAbs Therapeutics0.00%+0.23%+88.74%+80.38%-40.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.1598 of 5 stars3.52.00.04.42.62.50.6AVDLAvadel Pharmaceuticals2.9603 of 5 stars3.63.00.00.03.51.70.6SDGRSchrodinger3.102 of 5 stars3.33.00.00.03.13.30.6YMABY-mAbs Therapeutics2.4431 of 5 stars2.94.00.00.01.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.00Buy$11.5080.82% UpsideAVDLAvadel Pharmaceuticals 3.14Buy$19.6733.24% UpsideSDGRSchrodinger 2.67Moderate Buy$27.8342.66% UpsideYMABY-mAbs Therapeutics 1.80Reduce$9.6212.54% UpsideCurrent Analyst Ratings BreakdownLatest YMAB, SDGR, AVDL, and ARDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $20.008/18/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $19.008/15/2025SDGRSchrodingerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $20.008/14/2025SDGRSchrodingerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.008/14/2025SDGRSchrodingerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.008/8/2025AVDLAvadel PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/8/2025AVDLAvadel PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/8/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $24.008/6/2025ARDXArdelyxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$8.00 ➝ $9.008/6/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$11.00 ➝ $8.608/5/2025YMABY-mAbs TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$8.60(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M4.59N/AN/A$0.73 per share8.71AVDLAvadel Pharmaceuticals$169.12M8.47N/AN/A$0.77 per share19.17SDGRSchrodinger$207.54M6.92N/AN/A$5.78 per share3.38YMABY-mAbs Therapeutics$87.68M4.43N/AN/A$2.05 per share4.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.23N/A20.52N/A-14.60%-36.57%-13.42%10/30/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A246.00N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/11/2025 (Estimated)YMABY-mAbs Therapeutics-$29.67M-$0.50N/AN/AN/A-26.03%-24.60%-18.89%11/14/2025 (Estimated)Latest YMAB, SDGR, AVDL, and ARDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025YMABY-mAbs Therapeutics-$0.27-$0.07+$0.20-$0.07$18.40 million$19.52 million8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 million8/4/2025Q2 2025ARDXArdelyx-$0.13-$0.08+$0.05-$0.08$82.69 million$97.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.444.304.03AVDLAvadel PharmaceuticalsN/A2.792.38SDGRSchrodingerN/A3.303.30YMABY-mAbs TherapeuticsN/A4.003.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%AVDLAvadel Pharmaceuticals69.19%SDGRSchrodinger79.05%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%AVDLAvadel Pharmaceuticals5.20%SDGRSchrodinger21.00%YMABY-mAbs Therapeutics19.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90240.98 million229.42 millionOptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableSDGRSchrodinger79073.61 million58.15 millionOptionableYMABY-mAbs Therapeutics15045.44 million36.49 millionOptionableYMAB, SDGR, AVDL, and ARDX HeadlinesRecent News About These CompaniesY-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?September 1 at 10:56 AM | zacks.comY-mAbs Therapeutics, Inc. $YMAB Stake Lifted by Acorn Capital Advisors LLCSeptember 1 at 7:36 AM | marketbeat.comStonepine Capital Management LLC Acquires New Stake in Y-mAbs Therapeutics, Inc. $YMABAugust 26, 2025 | marketbeat.comBrokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) PT at $9.62August 26, 2025 | americanbankingnews.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Reduce" from AnalystsAugust 25, 2025 | marketbeat.comY-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 19, 2025 | globenewswire.comAcquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics StockAugust 13, 2025 | insidermonkey.comY-mAbs Therapeutics (NASDAQ:YMAB) Posts Earnings Results, Beats Expectations By $0.20 EPSAugust 11, 2025 | marketbeat.comXTX Topco Ltd Purchases 70,686 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)August 10, 2025 | marketbeat.comA Look Ahead: Y-mAbs Therapeutics's Earnings ForecastAugust 9, 2025 | benzinga.comY-mAbs (YMAB) Q2 Revenue Falls 14%August 9, 2025 | aol.comAFederated Hermes Inc. Has $680,000 Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)August 9, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue EstimatesAugust 8, 2025 | zacks.comShareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public ShareholdersAugust 8, 2025 | businesswire.comY-mAbs Therapeutics (NASDAQ:YMAB) Downgraded by Brookline Capital Management to HoldAugust 8, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Cantor FitzgeraldAugust 8, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Truist FinancialAugust 8, 2025 | marketbeat.comY-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate DevelopmentsAugust 8, 2025 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)August 7, 2025 | prnewswire.comY-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 7, 2025 | businesswire.comHC Wainwright Reiterates "Neutral" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)August 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeYMAB, SDGR, AVDL, and ARDX Company DescriptionsArdelyx NASDAQ:ARDX$6.36 -0.02 (-0.31%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$6.34 -0.02 (-0.33%) As of 08/29/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Avadel Pharmaceuticals NASDAQ:AVDL$14.76 +0.14 (+0.96%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$15.05 +0.29 (+1.99%) As of 08/29/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Schrodinger NASDAQ:SDGR$19.51 -0.25 (-1.27%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$19.52 +0.00 (+0.03%) As of 08/29/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Y-mAbs Therapeutics NASDAQ:YMAB$8.55 +0.01 (+0.12%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.54 -0.01 (-0.06%) As of 08/29/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
